Physician profile
Jung Bae
NPI 1124119805
$2,444.99
in general payments reported to CMS, 2019-2025
23 companies · $270 in 2025
The $270 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $212 · 2020: $165 · 2021: $146 · 2022: $470 · 2023: $716 · 2024: $468 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,434 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,433.50 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $665.42 | 2022-2025 | Linzess, Viberzi, Creon |
| Astrazeneca Pharmaceuticals Lp | $238.04 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $211.44 | 2022-2025 | |
| Lilly USA, LLC | $183.47 | 2019-2024 | Mounjaro, Jardiance, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $168.37 | 2021-2025 | Jardiance |
| Amarin Pharma, INC. | $150.96 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $115.17 | 2019-2023 | Verquvo |
| Amgen INC. | $91.77 | 2020-2023 | Otezla, Repatha |
| Novo Nordisk INC | $88.96 | 2023-2025 | Ozempic, Rybelsus |
| Shield Therapeutics INC | $79.34 | 2023-2024 | Accrufer |
| Pfizer INC. | $74.14 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $56.89 | 2024 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.42 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $50.26 | 2022-2023 | |
| Allergan, INC. | $34.09 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $33.99 | 2024 | Voquezna |
| Gilead Sciences, INC. | $30.55 | 2023 | |
| Aimmune Therapeutics, INC. | $27.61 | 2025 | Zenpep |
| Novartis Pharmaceuticals Corporation | $22.20 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $20.43 | 2022 | |
| Vertical Pharmaceuticals, LLC | $19.31 | 2019 | |
| Ardelyx, INC. | $19.21 | 2025 | Ibsrela |
| Janssen Pharmaceuticals, INC | $11.95 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jung Bae listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.